Navigation Links
UCSF artificial kidney project tapped for accelerated FDA program
Date:4/9/2012

A UCSF-led effort to create an implantable artificial kidney for dialysis patients has been selected as one of the first projects to undergo more timely and collaborative review at the Food and Drug Administration.

The FDA announced today (April 9) that it had chosen three renal device projects to pilot a new regulatory approval program called Innovation Pathway 2.0, intended to bring breakthrough medical device technologies to patients faster and more efficiently.

The artificial kidney project, which is targeted for clinical trials in 2017, was selected for its transformative potential in treating end stage renal disease and for its potential to benefit from early interactions with the FDA in the approval process.

The FDA effort will involve close contact between the federal agency and device developers early in the development process to identify and address potential scientific and regulatory hurdles and create a roadmap for project approval. The goal is to improve the projects' overall chance of success, while reducing the time and cost of FDA review and maintaining safety. Lessons, the agency said, will inform approvals in other areas.

The artificial kidney project has brought together 40 researchers in nine laboratories nationwide under the guidance of Shuvo Roy, PhD, a bioengineer on the faculty of the UCSF School of Pharmacy. It aims to combine nano-scale engineering with the most recent advances in cellular biology to create an implantable device that would enable patients with chronic kidney failure to lead healthier and more productive lives, without external dialysis or immune suppressant medication.

"The new Pathway program is a clear signal to researchers that innovations in how we treat disease are needed and supported by the FDA," said Mary Anne Koda-Kimble, PharmD, dean of the UCSF School of Pharmacy. "We're so pleased the Kidney Project is in the vanguard as the program launches."

End-stage renal disease, or chronic kidney failure, affects nearly 2 million people worldwide, including more than 570,000 in the United States, and costs the nation almost $40 billion each year for treatment. The most effective treatment is kidney transplantation, but those organs are in short supply; last year, only 16,812 kidneys were available for transplant, leaving 92,000 patients on the waiting list, according to the Organ Procurement ant Transplant Network.

For projects like the artificial kidney, inclusion in the program could also build confidence among investors.

"This will help us with investors and funding agencies," said Roy, who has met with several possible investors and granting agencies to fund the expected $20 million it will cost to bring the artificial kidney through clinical trials. "One of the questions we always get is, 'How will the FDA handle this?' With the Innovative Pathway program, we will know the answer to that question."

The UCSF artificial kidney, or implantable Renal Assist Device (iRAD) would include thousands of microscopic filters as well as a bioreactor to mimic the metabolic and water-balancing roles of a real kidney.

The combined treatment has been proven to work for the sickest patients using a room-sized external model developed by a team member at the University of Michigan. Roy's goal is to apply silicon fabrication technology, along with specially engineered compartments for live kidney cells, to shrink that large-scale technology into a device the size of a coffee cup. The device would then be implanted in the body, allowing the patient to live a more normal life.


'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related biology news :

1. Artificial wetlands can provide benefits over the long haul
2. Artificial womb unlocks secrets of early embryo development
3. Chemists synthesize artificial cell membrane
4. SmartActions Artificial Intelligence IVR Solution Receives PCI Certification
5. Human, artificial intelligence join forces to pinpoint fossil locations
6. NIH awards group $4.5 million for smart artificial pancreas technology
7. Oranges and mandarins are inspected using artificial vision
8. SynCardias Total Artificial Heart Rescues LVAD Patient with Right Ventricular Failure
9. Artificial lung mimics real organs design and efficiency
10. Caltech researchers create the first artificial neural network out of DNA
11. Using artificial, cell-like honey pots to entrap deadly viruses
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF artificial kidney project tapped for accelerated FDA program
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, ... funding to three startups through the UConn Innovation Fund. The $1.5 million UConn ... affiliated with UConn. , The UConn Innovation Fund provides investments of up to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant from ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , the ... and healthcare industries, is pleased to announce Holger Braemer as Vice President ... Europe GmbH” based in Germany. , Braemer is an integral part of USDM’s ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq ... applications, announced today that Chief Executive Officer (CEO) Debbie Gustafson has been appointed ... the global industry association connecting the electronics manufacturing supply chain. The mission of ...
Breaking Biology Technology: